

PerCP/Cy5.5 anti-mouse CD4

Catalog # / Size: 1102700 / 100 µg
1102695 / 25 µg

Clone: RM4-5

Isotype: Rat IgG2a, κ


Immunogen: BALB/c mouse thymocytes

Reactivity: Mouse

Preparation: The antibody was purified by affinity chromatography, and conjugated with PerCP/Cy5.5 under optimal conditions. The solution is free of unconjugated PerCP/Cy5.5 and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Concentration: 0.2



C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) PerCP/Cy5.5 and CD3 PE.

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 microg per 10⁶ cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cy5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Application Notes: The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4⁺ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, *in vivo* depletion of CD4⁺ cells¹, and immunohistochemistry of acetone-fixed frozen tissue sections^{2,3,11} and paraffin-embedded sections¹¹. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100520).

- Application References:**
1. Kruisbeek AM. 1991. *In Curr. Protocols Immunol.* pp. 4.1.1-4.1.5. (Block, Deplete)
 2. Nitta H, *et al.* 1997. *Cell Vision* 4:73. (IHC)
 3. Fan WY, *et al.* 2001. *Exp. Biol. Med.* 226:1045.
 4. Muraille E, *et al.* 2003. *Infect. Immun.* 71:2704. (IHC)
 5. León-Ponte M, *et al.* 2007. *Blood* 109:3139. (FC)
 6. Bourdeau A, *et al.* 2007. *Blood* doi:10.1182/blood-2006-08-044370. (FC)
 7. Matsumoto M, *et al.* 2007. *J. Immunol.* 178:2499. [PubMed](#)
 8. Shigeta A, *et al.* 2008. *Blood* 112:4915. [PubMed](#)
 9. Zaborsky N, *et al.* 2010. *J. Immunol.* 184:725. [PubMed](#)
 10. Rodrigues-Manzanet R, *et al.* 2010. *P. Natl Acad Sci USA* 107:8706. [PubMed](#)
 11. Whiteland JL, *et al.* 1995. *J. Histochem. Cytochem.* 43:313. (IHC)
 12. White CE, *et al.* 2015. *J Immunol.* 194:697. [PubMed](#)

13. Drees J, *et al.* 2015. *Anticancer Res.* 35:843. [PubMed](#)
 14. Sharma SK, *et al.* 2015. *J Immunol.* 194:5529. [PubMed](#)
 15. Castiglioni A, *et al.* 2015. *PLoS One.* 10:128094. [PubMed](#)
-

Description: CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes and a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a co-receptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosine kinase lck.

Antigen
References:

1. Barclay A, *et al.* 1997. *The Leukocyte Antigen FactsBook* Academic Press.
2. Bierer BE, *et al.* 1989. *Annu. Rev. Immunol.* 7:579.
3. Janeway CA. 1992. *Annu. Rev. Immunol.* 10:645.